focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEkf Diagnostics Regulatory News (EKF)

Share Price Information for Ekf Diagnostics (EKF)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 33.00
Bid: 32.40
Ask: 32.90
Change: 0.00 (0.00%)
Spread: 0.50 (1.543%)
Open: 32.60
High: 33.50
Low: 32.20
Prev. Close: 33.00
EKF Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.3 - EKF Diagnostics Holdings Plc

25 Aug 2015 11:54

KILLIK & CO LLP - Form 8.3 - EKF Diagnostics Holdings Plc

KILLIK & CO LLP - Form 8.3 - EKF Diagnostics Holdings Plc

PR Newswire

London, August 25

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Full name of discloser:Killik & Co LLP
(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offereeEKF Diagnostics Holdings Plc
(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: No
(e) Date position held/dealing undertaken: For an opening position disclosure, state the latest practicable date prior to the disclosure24/08/2015
(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer? If it is a cash offer or possible cash offer, state “N/A” No

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:
InterestsShort positions
Number%Number%
(1) Relevant securities owned and/or controlled:4,570,8771.08
(2) Cash-settled derivatives:
(3) Stock-settled derivatives (including options) and agreements to purchase/sell:
TOTAL:4,570,8771.08

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists: n/a
Details, including nature of the rights concerned and relevant percentages:

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant securityPurchase/saleNumber of securitiesPrice per unit

(b) Cash-settled derivative transactions

Class of relevant securityProduct description e.g. CFDNature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short positionNumber of reference securitiesPrice per unit

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant securityProduct description e.g. call optionWriting, purchasing, selling, varying etc.Number of securities to which option relatesExercise price per unitType e.g. American, European etc.Expiry dateOption money paid/ received per unit

(ii) Exercise

Class of relevant securityProduct description e.g. call optionExercising/ exercised againstNumber of securitiesExercise price per unit

(d) Other dealings (including subscribing for new securities)

Class of relevant securityNature of dealing e.g. subscription, conversionDetailsPrice per unit (if applicable)

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”
None

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state “none”
None

(c) Attachments

Is a Supplemental Form 8 (Open Positions) attached?No

Date of disclosure:25/08/2015
Contact name:Heidi Richer
Telephone number:020 7337 0400

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

Date   Source Headline
13th May 20137:00 amRNSFirst PointMan DNA enrichment products launched
15th Apr 20131:34 pmRNSPublication of Annual Report & Notice of AGM
18th Mar 20137:00 amRNSFinal Results
4th Mar 20137:00 amRNSEstablishment of EKF Molecular & Acquisition
18th Jan 20137:00 amRNSPre-close Trading Update
21st Dec 20123:53 pmRNSDirectors' Exercise of Options
17th Dec 20127:00 amRNSHolding(s) in Company
27th Nov 20124:32 pmRNSHolding(s) in Company
9th Nov 20127:00 amRNSIssue of Equity
24th Sep 20127:00 amRNSHalf Yearly Report
5th Sep 20127:00 amRNSTrading Update
14th Aug 20127:00 amRNSNICE guidance on type 2 diabetes
10th Aug 20127:00 amRNSHemoCue settlement agreement
17th Jul 20127:00 amRNSLicensing agreement for kidney markers
16th Jul 20123:05 pmRNSHolding(s) in Company
16th Jul 20127:00 amRNSQuo-Lab CE marking & Commercial launch
12th Jul 20121:11 pmRNSHolding(s) in Company
28th Jun 20127:00 amRNSDirector's Share Options
26th Jun 201210:30 amRNSHolding(s) in Company
23rd May 20121:00 pmRNSResult of AGM
11th May 20127:00 amRNSUpdate on Disposal of IBL AG
20th Apr 201211:18 amRNSPublication of Annual Report & Notice of AGM
18th Apr 20124:50 pmRNSHolding(s) in Company
5th Apr 20127:00 amRNSDirectors' Exercise of Options
5th Apr 20127:00 amRNSChina Patent Grant
3rd Apr 20121:47 pmRNSHolding(s) in Company
27th Mar 20127:00 amRNSDisposal of International Brand Licensing AG
26th Mar 20128:18 amRNSAdviser Change of Name
21st Mar 20127:00 amRNSFinal Results
20th Mar 20127:00 amRNSAppointment of Group Head of Sales
16th Mar 20127:00 amRNSTrading Update & Notice of Final Results
8th Mar 20127:00 amRNSUS Patent Grant
6th Feb 20127:00 amRNSNew US contract win
30th Jan 20122:08 pmRNSHolding(s) in Company
19th Jan 20127:00 amRNSPre-Close Trading Update
30th Nov 20117:00 amRNSContract win
29th Nov 20117:00 amRNSUpdate on US market expansion
24th Oct 20115:53 pmRNSHolding(s) in Company
24th Oct 20115:51 pmRNSHolding(s) in Company
12th Oct 201112:42 pmRNSHolding(s) in Company
7th Oct 20113:44 pmRNSHolding(s) in Company
29th Sep 20115:14 pmRNSHolding(s) in Company
28th Sep 20117:01 amRNSDirectorate Change
28th Sep 20117:00 amRNSHalf Yearly Report
27th Sep 20117:00 amRNSChange of Adviser
23rd Sep 20111:26 pmRNSNotice of Results
6th Jul 20113:48 pmRNSResult of AGM
29th Jun 20119:45 amRNSDirectors' Dealings
22nd Jun 20117:00 amRNSHolding(s) in Company
20th Jun 201111:37 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.